INTRODUCTION
Human rhinovirus (HRV) is a primary cause of the common cold and is the virus most frequently detected in children and adults exhibiting exacerbations of asthma [1] . Despite the frequency of HRV-associated respiratory disease, its pathogenesis and the intracellular/immunologic mechanisms that link HRV illness to common cold symptoms and asthma exacerbations are understood incompletely [2] .
Several reports suggest that the pathology induced by HRV respiratory infections and allergic airway inflammation in asthma is a consequence of host defense and inflammatory responses including cytokine elaboration and the recruitment of select immune cells [3] [4] [5] [6] . Airway inflammation in asthma is typified by the presence of Th2 lymphocytes and elaboration of cytokines and chemokines associated with T lymphocyte recruitment and activation [3, 5] . However, the inflammatory response in asthma is multifaceted, involving many cell types and inflammatory mediators, including cytokines characteristic of Th1 inflammation [3] . In this regard, a Th1-associated chemokine, IFN-␥-inducible protein-10 (IP-10; CXCL10), a CXCR3 ligand that selectively recruits activated Th1 lymphocytes and NK cells, has been implicated recently in modulating airway inflammation in asthma [7, 8] . It has been proposed that IP-10 contributes to airway inflammation and airway hyperresponsiveness in a murine model of asthma [4] . Consistent with these findings, it has been reported that human bronchial epithelium and submucosa from asthmatic individuals have significantly greater detectable levels of IP-10 mRNA as compared with normal, control individuals [6] . Moreover, submucosal macrophages and neutrophils are the prominent sources of IP-10 mRNA and express significantly higher levels of IP-10 mRNA in asthmatics as compared with control individuals. Furthermore, segmental bronchoprovocation of allergic-asthmatic individuals with allergen results in increased IP-10 levels and T lymphocyte numbers in bronchoalveolar lavage (BAL) fluid, and there is a direct correlation between airway T lymphocyte numbers and IP-10 levels [9] . Similarly, individuals challenged with HRV16 intranasally have significantly greater levels of IP-10 protein in nasal lavage fluid, which correlates positively with viral titer and T lymphocyte number in nasal secretions as well as respiratory symptom severity [7] . Taken together, it is clear that IP-10 is associated with airway inflammation and lymphocytic infiltration exhibited with asthma and rhinovirus infection; however, the functional role of IP-10 in asthma and the cellular source and intracellular regulation of IP-10 production in response to inflammatory stimuli, specifically HRV, are not well-defined.
Monocytic cells (monocytes and macrophages) are the predominant immune cells present in the lumen of the lower airway, and activation of these cells represents one of the first steps in natural immunity toward virus infection [10, 11] . The ability of HRV to infect upper and lower airway epithelium with similar efficacy thereby suggests that monocytic cells likely have direct interaction with HRV in vivo [12] . In addition, given the close association of augmented inflammation of the lower airways and worsening of asthma, HRV interaction with lower airway macrophages is likely relevant to asthma exacerbations [12] [13] [14] . Previous studies from our laboratory and others demonstrate that monocytic cells and epithelial cells express the major group HRV attachment molecule ICAM-1 and respond to in vitro HRV challenge with the release of a numerous cytokines [10, [15] [16] [17] . Although recent reports have demonstrated that HRV replication is required for the induction of IP-10 expression by primary epithelial cells, it remains unclear if HRV is capable of promoting IP-10 expression in monocytic cells, which do not sustain a productive infection with HRV [7] .
Expression of the IP-10 gene is regulated by several putative transcription factors including IFN-stimulated response element, STAT, C/EBP-␤, NF-B, and AP-1 [7] . Two recent studies using epithelial cells examined the involvement of intermediate production of type I IFNs, well-known activators of STAT factors, in modulating HRV-induced IP-10 expression; however, conflicting results linking type I IFN receptor ligation to HRV-stimulated IP-10 expression have been reported [7, 18] . Therefore, a better understanding of the intracellular signaling molecules modulating HRV-induced IP-10 expression in airway cells and the role of monocytic cells in IP-10 elaboration in response to HRV challenge is needed. Accordingly, this study addressed the hypotheses that HRV can induce IP-10 expression by monocytes/macrophages, that intracellular HRV16 replication is not required for IP-10 protein expression in these cells, and that HRV16-stimulated IP-10 release is modulated by type I IFN receptor/JAK/STAT pathway activity. Our findings demonstrate for the first time that exposure of primary monocytic cells to native or replication-defective HRV results in robust IP-10 release that is similar to the level of IP-10 release previously reported by HRV-stimulated epithelial cells [7] . Furthermore, this work supports a model, wherein HRV16-induced IP-10 release by monocytic cells is modulated via autocrine/paracrine action of type I IFNs and subsequent JAK/STAT pathway activity. 
MATERIALS AND METHODS

Reagents
Cell culture
Human alveolar macrophages were obtained from atopic donors undergoing BAL at the University of Wisconsin Hospital and Clinics (Madison). Human PBMC were obtained from atopic or nonatopic donors at the University of Wisconsin Hospital Clinics, and peripheral blood monocytes were isolated from the PBMC before plating. The Human Subjects Committee of the University of Wisconsin Hospital approved the experimental protocols. Isolated human BAL macrophages and human peripheral blood monocytes were resuspended in RPMI-1640 medium, supplemented with 10% FBS (Mediatech, Herndon, VA), 2 mM sodium pyruvate, 2 mM L-glutamine, and 100 U/ml penicillin/streptomycin (complete medium), and plated in 24-well tissueculture plates (Corning Inc./Costar, Acton, MA) at a density of 1 ϫ 10 6 cells/mL (0.5 mL/well) or 12-well tissue-culture plates at a density of 2 ϫ 10 6 cells/mL (1 mL/well). Following a 2-h incubation, cells were rinsed two times with HBSS (Mediatech) containing 2% heat-inactivated bovine calf serum (HBSS-BCS), and media were replaced with RPMI-1640 medium supplemented with 1% FBS for immunoblotting experiments or complete medium for experiments examining cytokine elaboration. Cells were incubated overnight at 37°C in a humidified atmosphere with 5% CO 2 .
Isolation of alveolar macrophages
Bronchoscopy and BAL were conducted as described [19] . Briefly, in unchallenged, atopic individuals, two bronchopulmonary segments were identified with a fiberoptic bronchoscope, and lavage was performed with 160 mL 0.9% saline in each bronchopulmonary segment. The BAL fluid recovered from the bronchopulmonary segments was combined and filtered through mesh, and the BAL cells were isolated by centrifugation (400 g for 10 min at 4°C). The BAL cells were washed twice with HBSS supplemented with 2% newborn calf serum (400 g for 10 min at 4°C), and the resulting cell population was evaluated by differential morphological analysis (Diff-Quick Scientific Products, McGaw Park, IN). Morphological examination indicated that typical BAL cell populations were primarily comprised of macrophages (87%), and the remaining cells were primarily lymphocytes (7%), neutrophils (1%), and epithelial cells (2%).
Purification of human monocytes
Heparinized whole blood was obtained from volunteer donors at the University of Wisconsin Hospital and enriched for PBMC via centrifugation (700 g) through a Percoll monolayer (1.090 g/mL Percoll) for 20 min at room temperature (RT). A suspension of erythrocytes and leukocytes (RBC) was also obtained below the Percoll monolayer following centrifugation. Platelets were reduced by subjecting PBMC to three consecutive washes (350 g, 250 g, 150 g for 12 min at RT) in HBSS-BCS. The RBC suspension (0.5 mL) and 45 mL HBSS-BCS were added to 10 8 PBMC, followed by centrifugation at 250 g for 12 min at RT. The cell pellet was resuspended in 1 mL HBSS-BCS and incubated with 150 L RosetteSep human monocyte enrichment cocktail for 20 min at RT. The cells were enriched for monocytes by centrifugation at RT over lymphocyte separation medium (Mediatech) for 20 min at 1400 g and washed by centrifuging at RT with HBSS-BCS for 10 min at 350 g. The monocyte pellet was resuspended in complete medium and plated in tissueculture plates as denoted above. The resulting cell population consisting of adherent and nonadherent monocytes was 85-90% CD14 ϩ (nϭ4) as determined by flow cytometry.
Production and purification of HRV16, neutralred (NR)-inactivated HRV16, and 35 
S-labeled HRV16
Human RV16 was grown in HeLa cells as described previously; in addition, NR-containing HRV16 and 35 S-labeled HRV16 were grown in HeLa cells, whereupon the tissue-culture medium was supplemented with 10 g/mL NR dye at 30 min postinfection and/or 35 S-methionine (1 mCi per 4ϫ10 8 cells; Amersham, Piscataway, NJ) at 3.25 h postinfection, respectively [20 -22] . Infected HeLa cells were harvested 8 h postinfection, and virions were purified from the infected cell lysate by centrifugation through a sucrose cushion and subsequently sedimented through a sucrose-step gradient to remove contaminants as described previously [20, 21] . The yield of the HRV16 particles was measured optically, wherein an OD260 unit correlates with 0.133 g (9.4ϫ10 12 virions) virion protein [21] . To inactivate NR-containing HRV16, the viral RNA genome was fragmented by exposure to a 15-W white fluorescent light located 3 inches above the purified viral suspension for 15 min. The multiplicity of infection (MOI), which refers to the number of infectious HRV particles per cell (typically one infectious HRV particle per 300 total particles), was determined by measuring the infectivity of the virions in HeLa cell monolayers as described elsewhere [21] . The NR-containing virions exhibited over 99% reduction in infectivity following 15 min of white fluorescent light illumination.
HRV16 treatment with WIN52035 or low pH conditions
Sucrose-purified HRV16 was treated with WIN52035 (20 g/mL) in RPMI 1640 at RT with agitation for 1 h and added to cells at a final concentration of 2 g/mL WIN52035. Sucrose-purified HRV16 was treated with low pH (pHϽ4) in RPMI 1640 at RT with agitation for 30 min with subsequent pH neutralization (pHϭ7-7.5) for 2 min prior to stimulation of cells. No viral infectivity in HeLa cells could be detected following WIN52035 or low pH treatment of HRV16.
HRV16 and NR-inactivated HRV16 attachment assay
Human peripheral blood monocytes were resuspended in Dulbecco's PBS (DPBS; Cambrex Bio Science, Walkersville, MD) and aliquoted into four 0.1% BSA-coated Eppendorf tubes at a cell density of 1 ϫ 10 7 monocytes/250 L. Appropriate cell suspensions were treated with anti-ICAM-1 antibody (30 g/mL) or isotype control (IgG1; 30 g/mL) for 30 min at 4°C. Following incubation, the monocytes were sedimented by centrifugation at 500 g for 5 min at 4°C, and the supernatants were discarded. The monocytes were resuspended with 250 L DPBS, supplemented with 0.1% BSA and 35 S-labeled HRV16 (1.6ϫ10 8 virions/L) or 35 S-labeled, NR-inactivated HRV16 (1.6ϫ10 8 virions/L), and incubated for 1 h at RT with agitation to allow virus attachment. Following incubation, the monocytes were sedimented by centrifugation at 500 g for 5 min at 4°C. The cells were next subjected to three consecutive washes (500 g for 5 min at 4°C) using DPBS supplemented with 0.1% BSA. Cells were lysed in DPBS containing 0.2% SDS and 0.05% NaOH. Input 35 S-labeled virus and cell lysates (in triplicate) were measured for 35 S cpm using a liquid scintillation analyzer (Packard, Meriden, CT). The number of cell-associated virions was determined by normalizing the total cpm/sample to specific activity (cpm/virion). The number of virions/cell was quantified by normalizing the number of cell-associated virions to the number of cells used {virions/cellϭ[(total cpm/sample)/(cpm/virion)]/1 ϫ 10 7 monocytes}.
Immunoblotting
Peripheral monocytes and BAL macrophages were lysed with SDS sample buffer (75 L SDS sample buffer per 2ϫ10 6 cells), and protein concentrations for each sample were quantified using bicinchoninic acid protein assay (Endogen/Pierce). Equivalent amounts of protein for each sample were resolved on SDS-PAGE gels and transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA). The membranes were blocked in 5% milk in TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween 20), and immunoblotting was performed according to the manufacturer's protocols. The immunoreactive bands were visualized using SuperSignal West Pico chemiluminescent substrate (Endogen/Pierce) and Epichemi II darkroom (UVP, Upland, CA) equipped with a 12-bit cooled charged-coupled device camera.
Detection of IP-10/IFN-␣ protein release by monocytic cells
Peripheral monocytes and BAL macrophages were plated in 24-well plates as described above. Following overnight incubation, cells were pretreated with or without neutralizing antibodies as described in figure legends and subsequently stimulated with control vehicle, HRV16, IFN-␣, or IFN-␥ for 24 h at 37°C. Following incubation, cell supernatants were harvested and frozen at -80°C until analysis. The protein levels of IP-10 and/or IFN-␣ were measured using commercial sandwich ELISA kits according to the manufacturer's protocols (R& D Systems, Minneapolis, MN, and Endogen/Pierce, respectively).
Cell viability assay
Isolated human peripheral blood monocytes were resuspended in complete medium and plated in 96-well tissue-culture plates at a density of 1 ϫ 10 6 cells/mL (0.1 mL/well). Cells were pretreated with blocking/isotype antibodies and stimulated with control vehicle or treated/untreated virus for 24 h at 37°C. Following incubation, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and the electron-coupling reagent phenazine methosulfate were added to monocytes according to the manufacturer's protocol (Promega, Madison, WI), and the mixtures were incubated for 1 h at 37°C in a humidified atmosphere with 5% CO 2 . During this incubation period, MTS is converted to aqueous, soluble formazan by endogenous dehydrogenase enzymes; thus, the quantity of formazan product, as measured by the amount of absorbance at 490 nm using an ELx800 ELISA microplate reader (Bio-Tek Instruments Inc., Winooski, VT), is directly proportional to the number of metabolically active/viable cells.
RESULTS
HRV16 induces IP-10 protein release by monocytic cells in a time-and dose-dependent manner
Preliminary analysis of gene expression by human peripheral blood monocytes stimulated with HRV16 (MOIϭ10) or control vehicle for 4 h was conducted using oligonucleotide mircroarrays (Affymetrix HuGeneFL GeneChip). We observed that HRV16 stimulated an increase in several chemokine transcripts, and the most robust responses (Ͼ30-fold) were seen for IP-10, MCP-1, MCP-2, and IFN-inducible T cell-␣ chemoattractant, whereas smaller responses (three-to 16-fold) were noted for IL-8, MCP-3, and MIP-1 (data not shown). These data suggest that monocytic cells are active participants in promoting host chemokine elaboration following an in vivo HRV challenge, and given the importance of IP-10 to the recruitment of lymphocytes and NK cells, we tested the concept that monocytes/macrophages respond to HRV16 challenge with the production/release of IP-10 protein. In this regard, Figure 1 reveals that primary BAL macrophage exposure to HRV16 does result in robust IP-10 protein release ( Fig. 1A ; HRV16ϭ26.7Ϯ4.3 ng/mL vs. control vehicleϭ0.32Ϯ0.22 ng/ mL; Pϭ0.003). Human peripheral blood monocytes were also examined for IP-10 release following HRV16 (MOIϭ10) challenge at various time intervals, which likely correspond to HRV16 exposure in vivo (Fig. 1B) . Increased IP-10 release from monocytes was detected 8 h post-HRV16 infection. Monocyte exposure to HRV16 for 24 h resulted in robust IP-10 release (9.95Ϯ1.8 ng/mL; control IP-10 release Յ0.014Ϯ0.007 ng/mL), which remained throughout 72 h. Peak levels of IP-10 release (14.3Ϯ2.0 ng/mL) by monocytes were detected 48 h post-HRV16 challenge, indicating a time-dependent release of IP-10 by human monocytes (PϽ0.0001). Similarly, Spurrell et al. [7] saw peak levels of IP-10 release by human airway epithelial cells at 48 h post-HRV16 infection. It is noteworthy that the levels of IP-10 release by monocytes (14.3Ϯ2.0 ng/ mL) and macrophages (26.7Ϯ4.3 ng/mL) following HRV16 inoculation are similar to that exhibited by HRV16-stimulated epithelial cells (15.6Ϯ5.1 ng/mL [7] ). Although the monocytes used here were obtained from 10 different individuals, including five allergic-asthmatic and five nonatopic patients, no significant difference in HRV16-induced IP-10 release was detected between the allergic-asthmatic and nonatopic donors (Pϭ0.29).
To assess if HRV16-induced IP-10 release by monocytic cells is dose-dependent, human monocytic cells were exposed to varying doses of HRV16 (MOIϭ0, 0.1, 1, 10, 100) for 24 h (Fig. 2) . Exposure of BAL macrophages and monocytes to HRV16 at a MOI of 0.01 had little to no effect on IP-10 protein release. However, a dose-dependent release of IP-10 was detected following treatment with HRV16 at a MOI of 0.1-100 (BAL macrophages, Pϭ0.004; monocytes, Pϭ0.0002). It is interesting that similar levels of IP-10 release by monocytic cells were detected following HRV16 challenge in a MOI range of 1-10, and lower levels of IP-10 release were seen when the cells were challenged with HRV16 at a MOI of 100 or MOI less than 1. These data demonstrate robust levels of IP-10 release by monocytic cells upon exposure to predicted physiological concentrations of HRV16 (MOIՅ10).
Disrupting HRV16-ICAM-1 interaction attenuates HRV16-stimulated IP-10 release by monocytic cells
The major group HRV (including HRV16) receptor is ICAM-1 [23] . To confirm that HRV16-stimulated IP-10 release by monocytic cells is HRV-specific, we used three methods to abrogate HRV16-ICAM-1 interaction: pretreatment of monocytic cells with an anti-ICAM-1 mAb, which has been shown previously to inhibit HRV16 attachment to human monocytes [10] ; pretreatment of HRV16 with WIN52035, which is a compound that induces conformational changes in the region of the HRV capsid that binds to ICAM-1 [22, 24] ; and neutralization of HRV16 via pretreatment at low pH (pHϽ5.0), which facilitates viral uncoating [25] . As shown in Figure 3 , neutralization of cell surface-expressed ICAM-1 on monocytes, using anti-ICAM-1, abolished the ability of HRV16 to induce IP-10 release, whereas the isotype control, IgG1, had little effect. Furthermore, inhibiting the ability of HRV16 to bind ICAM-1, via pretreatment of HRV16 with WIN52035 or low pH, also attenuated HRV16-stimulated IP-10 release by monocytes. The decrease in IP-10 release by monocytic cells upon impeding HRV16-ICAM-1 interaction was not a result of cytotoxic effects of the inhibitory methods, as mean cell viability for all treatments was Ն98% relevant to control treatment (nϭ3; MTS assay as described in Materials and Methods). These data demonstrate that HRV16-induced IP-10 release by monocytic cells requires ICAM-1 for viral attachment and/or signal transduction.
Human monocytes release IP-10 following exposure to native and NR-inactivated HRV16
Previous studies by us and others [10, 17] have suggested that monocytic cells do not support a productive infection with HRV16. In contrast, airway epithelial cells are the primary site of HRV16 replication and require viral replication for IP-10 induction [7, 18] . To assess if HRV16 replication is required for IP-10 production by human monocytes, we used NR-containing HRV16, which when exposed to white fluorescent light, displays severely reduced HRV16 infectivity. However, HRV16 inactivation by this method did not affect virus attachment to cells, as human 35 S-RV16-and 35 S-NR-inactivated HRV16 incubated with human monocytes for 1 h showed no significant difference in the number of particles associated with the cells (Fig. 4A) . Moreover, the attenuation of HRV16 association with monocytes in the presence of anti-ICAM-1 ensures that HRV16 attachment is ICAM-1-dependent. It is interesting that NR-inactivated HRV16 retained the ability to stimulate IP-10 release by human monocytes following a 24-h incubation at a level similar to that exhibited by native HRV16 (Fig. 4B ). These data reveal that unlike HRV16 replication requirements in epithelial cells, HRV16 replication is not required for monocytic cell activation and subsequent cytokine elaboration. JAK/STAT and p38 kinase activity modulate HRV16-induced IP-10 release by human monocytes Putative transcriptional activators of IP-10 gene expression include the STAT factors [7] . Accordingly, the present study examined the STAT isoform 1 (STAT1) phosphorylation state following human monocyte exposure to HRV16 (MOIϭ10) for various time periods. Immunoblot analysis indicated that HRV16 stimulated STAT1 phosphorylation in monocytes in a time-dependent manner (Fig. 5A) . The phosphorylation of STAT1 in monocytes was not detectable until 2 h post-HRV16 inoculation, whereupon the phosphorylation persisted, although to a lesser degree, throughout 8 h. In addition, monocytes were stimulated with IFN-␥, a well-known activator of STAT1, as a positive control, whereas treatment with anisomycin was used as a negative control for STAT1 phosphorylation. As STAT1 is phosphorylated in monocytes inoculated with HRV16 and is a putative, transcriptional regulator of IP-10, these data suggest that STAT1 activity participates in mediating HRV16-induced IP-10 release.
Activation of STAT molecules occurs upon phosphorylation of select tyrosine residues by members of the JAK family (JAK1, -2, and -3 and Tyk 2) of tyrosine kinases [26] . To determine whether JAK/STAT pathway activity modulates IP-10 production by monocytes following HRV16 challenge, the effect of JAK-I, which blocks JAK family member (inhibits JAK1, -2, and -3 and Tyk2) activity on HRV16-induced IP-10 release by monocytes, was evaluated. The JAK inhibitor significantly attenuated HRV16-stimulated IP-10 protein in a dose-dependent manner (Pϭ0.0001; Fig. 5B ) via a noncytotoxic mechanism (mean viabilityϭ92%; data not shown; nϭ3). These data suggest that HRV16-induced IP-10 release by monocytic cells is mediated via JAK/STAT pathway activity.
We reported previously that HRV16 stimulates p38 kinase activity, which mediates, at least in part, MCP-1 protein release by primary monocytes and macrophages [17] . In the present study, we examined further if p38 kinase activity modulates HRV16-induced IP-10 release by monocytes. Pretreatment of monocytes with a selective p38 kinase inhibitor (10 M SB203580) significantly attenuated HRV16-induced IP-10 release (Pϭ0.02), whereas pretreatment with the inactive analog of the inhibitor (10 M SB202474) caused no reduction (Fig. 5C ).
Intermediate production of a soluble factor mediates HRV16-stimulated STAT1 phosphorylation in human monocytes
Our previous studies have demonstrated that intracellular signaling events in human monocytic cells are initiated within 15 min of HRV16 stimulation [17] . The delayed kinetics of HRV16-stimulated STAT1 phosphorylation in monocytes suggests that this process may be secondary to the release/action of an autocrine/paracrine factor (Fig. 5A) . To test this idea, monocytes were exposed to control vehicle or HRV16 (MOIϭ10) for 2 h, followed by the transfer of the tissue-culture medium to untreated monocytes for 30 min, and the STAT1 phosphorylation status was then evaluated via immunoblotting. As shown in Figure 6A , HRV16 induced STAT1 phosphorylation in monocytes after a 2-h incubation (lane 2). It is interesting that the transfer of tissue-culture medium from monocytes exposed to HRV16 for 2 h to untreated monocytes resulted in STAT1 phosphorylation within 30 min (Fig. 6A, lane 6) . The presence of , or IFN-␥ (100 ng/mL) for the indicated times. Equivalent amounts of protein (50 g) for each sample were subjected to SDS-PAGE, and immunoblotting was conducted using antiphospho-STAT1 as described in Materials and Methods. A representative immunoblot displaying STAT1 phosphorylation in HRV16-stimulated monocytes is shown (nϭ3). (B) Effect of JAK-I on HRV16-stimulated IP-10 secretion by human monocytes, which were pretreated with or without control vehicle or increasing concentrations of JAK-I (0.003-1.0 M) for 2 h. Following pretreatment, the cells were incubated with control vehicle or HRV16 (MOIϭ10) for 24 h Data represent the mean Ϯ SEM from three independent experiments (Pϭ0.0001 by repeated-measure ANOVA analysis). (C) Effect of p38 kinase inhibition on HRV16-induced IP-10 production by human monocytes, which were pretreated with control vehicle or the active/ inactive forms of the p38 kinase inhibitor (activeϭ10 M SB203580; inactiveϭ10 M SB202474) for 30 min. Following pretreatment, the cells were stimulated with control vehicle or HRV16 (MOIϭ10) for 24 h. Data represent mean Ϯ SEM from three independent experiments (*, HRV16 vs.
HRV16ϩSB203580, PϽ0.05 by t-test).
HRV16 in the transfer medium was not responsible for STAT1 phosphorylation at 30 min, as HRV16 stimulation alone did not induce STAT1 phosphorylation within 30 min (Fig. 5A, lane 3; Fig. 6A, lane 8) . These findings demonstrate that HRV16-induced STAT1 phosphorylation requires, at least in part, the action of an autocrine/paracrine factor. The ability of IFN-␣/IFN-␥ to stimulate STAT1 phosphorylation in monocytes within 30 min further supports the idea of an autocrine/paracrine factor mediating HRV16-induced STAT1 phosphorylation (Figs. 5A and 6A, lanes 9 and 10; see Fig. 7A ).
Increase in IFN-␣ secretion by human monocytes following HRV16 challenge
Type I IFNs are produced by monocytic cells in response to various pathogens and are established activators of STAT1 [27] . Hence, autocrine/paracrine action of type I IFNs may mediate HRV16-induced STAT1 phosphorylation. This study tested if monocyte exposure to HRV16 stimulates IFN-␣ protein release. Human monocytes obtained from five different donors were challenged with control vehicle or HRV16 at a MOI of 10 for 24 h. As shown in Figure 6B , HRV16 induced a significant increase in IFN-␣ release by monocytes (Pϭ0.03). The detected amount of IFN-␣ released by monocytes following HRV16 is likely a conservative measurement of total IFN-␣ release, as several IFN-␣ isoforms exist, which are not detected by this ELISA assay and are likely expressed by monocytic cells upon exposure to HRV16. These data suggest that HRV16-stimulated IFN-␣ release acts in an autocrine/ paracrine manner to mediate STAT1 phosphorylation and IP-10 production.
IFN-␣ and IFN-␥ stimulate STAT1 phosphorylation and IP-10 release by human monocytes
Our findings demonstrate that HRV16 stimulates IFN-␣ release by human monocytes, which may mediate HRV16-induced STAT1 phosphorylation and IP-10 induction. Accordingly, monocytes were exposed to various concentrations of 
IFN-␣ or IFN-
Immunoblot analysis demonstrated that IFN-␣ and IFN-␥ up-regulated STAT1 phosphorylation in monocytes in a dose-dependent manner (Fig. 7A) . Moreover, IFN-␣ induced STAT1 phosphorylation to a similar level as that exhibited upon HRV16 stimulation. These findings support the concept that HRV16-stimulated STAT1 phosphorylation in monocytes likely occurs via autocrine/paracrine action of IFNs. In addition, IFN-␣ and IFN-␥ induced IP-10 release by human monocytes in a dose-dependent manner (Pϭ0.0008 for IFN-␣, and Pϭ0.0004 for IFN-␥; Fig. 7B ). Simultaneous stimulation of monocytes with HRV16 and IFN-␥ resulted in increased IP-10 release by monocytes, which was significantly greater than the level of IP-10 release exhibited by HRV16 or IFN-␥ stimulation alone (Pϭ0.006). The observation that HRV16 and IFN-␥ together stimulate IP-10 release by monocytes in an additive manner suggests that these stimuli induce IP-10 production via independent mechanisms. It is interesting that simultaneous stimulation of monocytes with HRV16 and IFN-␣ resulted in IP-10 secretion at levels similar to that induced by HRV16 stimulation alone, thereby suggesting that these stimuli induce IP-10 release via similar mechanisms. Taken together, these data support the idea that autocrine/paracrine action of type I IFN not only mediates HRV16-induced STAT1 phosphorylation in monocytic cells but IP-10 secretion as well.
Neutralization of the type I IFN receptor attenuates HRV16-stimulated STAT1 phosphorylation and IP-10 release by human monocytes
As HRV16-induced STAT1 phosphorylation and IP-10 release by monocytic cells are likely linked to autocrine/paracrine action of type I IFNs, this study evaluated the effect of neutralizing the type I IFN receptor on these processes. Independent stimulation of monocytes with HRV16, IFN-␣, or IFN-␥ resulted in STAT1 phosphorylation (Fig. 8A) . As expected of a receptor-mediated response, blocking ligand interaction with the type I IFN receptor using a neutralizing mAb (anti-IFN receptor type I) significantly suppressed IFN-␣-induced STAT1 phosphorylation but had no effect on IFN-␥-stimulated STAT1 phosphorylation in human monocytes. It is noteworthy that neutralization of the type I IFN receptor also attenuated STAT1 phosphorylation in monocytes challenged with HRV16. These findings support the concept that HRV16-induced STAT1 phosphorylation is mediated, at least in part, by autocrine/paracrine action of type I IFNs.
The effect of type I IFN receptor neutralization on HRV16-, IFN-␣-, or IFN-␥-induced IP-10 release by monocytes is consistent with the observed effects on STAT1 phosphorylation (Fig. 8A) . Monocytes exposure to HRV16 (MOIϭ10), IFN-␣ (10 ng/mL), or IFN-␥ (10 ng/ml) for 24 h resulted in similar levels of IP-10 secretion (Fig. 8B) . However, neutralizing the type I IFN receptor with anti-IFN receptor type I significantly attenuated type I IFN-␣-induced IP-10 release by monocytes (Pϭ0.0009) but had little to no effect on type II IFN-␥-induced IP-10 release (Pϭ0.72; Fig. 8B) . Furthermore, the presence of anti-IFN receptor type I significantly attenuated IP-10 release by monocytes challenged with HRV16 (Pϭ0.0005). Taken together, these data support the concept that HRV16 stimulates type I IFN release by monocytic cells, which subsequently mediates HRV16-induced STAT1 phosphorylation and IP-10 release.
DISCUSSION
Although the intracellular and immunologic mechanisms that mediate HRV-induced pathobiology of asthma remain unclear, it is evident that symptomatic infections are associated with elevated levels of chemokines in airway and nasal secretions as well as inflammatory cell recruitment into lung tissue, airway, and nasal passages [7, 28 -33] . For example, individuals challenged with HRV16 have significantly greater levels of IP-10 protein in nasal lavage fluid that positively correlates with viral titer and lymphocyte number in nasal secretions as well as respiratory symptom severity [7] . However, there is relatively little information about the cellular source and intracellular regulation of IP-10 protein production in response to HRV exposure. In this study, we demonstrate for the first time that monocytic cells, which are the predominant immune cells in the airway lumen, produce robust levels of IP-10 protein in response to HRV16 challenge, which is independent of viral replication. Furthermore, our data indicate that monocytic cell exposure to HRV16 results in STAT1 phosphorylation and that p38 kinase and JAK/STAT pathway activity are important in modulating HRV16-stimulated IP-10 production in monocytes. Our findings further indicate that monocytic cell exposure to HRV16 results in significantly elevated release of IFN-␣. Moreover, HRV16-induced STAT1 phosphorylation and robust release of IP-10 by monocytic cells are linked to type I IFN receptor ligation; therefore, these processes are likely modulated by autocrine/paracrine action of type I IFNs.
Human monocytes and macrophages do not support a productive HRV16 infection [10, 17] , yet our data demonstrate that monocytic cells do produce high levels of IP-10 in response to native and/or replication-defective HRV16 challenge. In contrast, HRV16-stimulated IP-10 expression in epithelial cells requires infection with virus capable of replication [7, 18] . A potential mechanism that may explain how HRV16 induces IP-10 release by monocytic cells without viral replication, which is required in epithelial cells, is that HRV16-ICAM-1 interaction at the cellular surface may be sufficient to initiate signal transduction and elicit IP-10 protein expression by monocytic cells. In this regard, previous studies have revealed that ICAM-1 cross-linking initiates rapid cytoplasmic signaling and subsequent phosphorylation and activation of stress-activated protein kinases [34, 35] . Furthermore, this idea is supported by our data demonstrating that blockade of HRV16-ICAM-1 interaction attenuates HRV16-induced IP-10 secretion by monocytic cells. Thus, HRV16 binding to ICAM-1 may initiate signal transduction via ICAM-1, or HRV16-ICAM-1 interaction may be important for HRV16 internalization and subsequent intracellular signaling. Of note, a previous report stated that a HRV16 particle has the capacity to bind ϳ60 soluble ICAM-1 molecules (one ICAM-1 molecule per icosahedral face of the capsid [25] ), which suggests that ICAM-1 oligomerization may be required for optimal HRV16-induced signal transduction via ICAM-1 or virus internalization. Our findings indicate that IP-10 release by monocytic cells is maximal following HRV16 stimulation with a MOI range of 1-10 and that lower levels of secreted IP-10 are detected upon stimulation with HRV16 at a MOI of 100. Thus, HRV16 at a MOI of 100 may saturate cell-surface ICAM-1 molecules, thereby preventing ICAM-1 oligomerization and resulting in lower levels of IP-10 secretion.
An alternative explanation for the disparity in monocytes and epithelial cell responsiveness to nonreplicative HRV16 is that HRV16 replication may not be required for IP-10 expression by airway epithelial cells similar to that exhibited by monocytic cells. In this regard, the two published reports suggesting that HRV16 replication is required for IP-10 expression by epithelial cells used UV-inactivated HRV16 to model replication-defective HRV16 [7, 18] . However, subjecting virus to UV irradiation may cross-link viral proteins in addition to introducing defects into the viral genome, thereby repressing the ability of the virus to interact with ICAM-1 or other potential surface recognition molecules. In support of this concern, our unpublished data indicate that UV-inactivated HRV16 exhibited over 80% reduction in binding to HeLa cells as compared with native HRV16 (nϭ3). In the present study, NR-inactivated HRV16 was replication-defective but maintained virus-cell association and retained the ability to induce IP-10 expression by monocytic cells.
Not only is the mechanism of signal transduction initiation by HRV16 unclear, but little is known about the intracellular regulation of HRV16-induced chemokine expression as well. The IP-10 promoter region contains consensus sites for activated STAT protein, NF-B, as well as AP-1 [7] . The transcription factor AP-1 is a well-known protein substrate of p38 kinase, and our previous studies demonstrated that HRV16 induces p38 kinase activity in primary monocytic cells [17] ; therefore, we proposed that p38 kinase activity likely modulates HRV16-induced IP-10 production. This idea was supported by our present study, which indicates that inhibition of p38 kinase activity significantly attenuates IP-10 production by monocytes following HRV16 challenge. Furthermore, our study is the first to report that HRV16 consistently stimulates STAT1 phosphorylation in primary monocytic cells isolated from 12 human donors and that JAK/STAT1 activity mediates, at least in part, IP-10 protein release by monocytes following HRV16 challenge. It is interesting that HRV16-induced STAT1 phosphorylation in monocytic cells did not occur until 2 h postinfection. In contrast, IFN-␣ and IFN-␥, well-known activators of STAT1, were able to elicit STAT1 phosphorylation in human monocytes with rapid kinetics (15 min, nϭ3, data not shown). Moreover, the transfer of tissue-culture medium from monocytes exposed to HRV16 for 2 h to untreated monocytes resulted in STAT1 phosphorylation within 30 min. Taken together, these findings suggest that STAT1 phosphorylation in monocytic cells following HRV16 challenge is likely mediated by the intervening production of soluble factors. Accordingly, a potential mechanism of HRV16-stimulated STAT1 phosphorylation and IP-10 protein production by monocytic cells involves the autocrine/paracrine action of secreted IFNs.
IFNs are essential regulators of various innate immune responses and initiate early host defense mechanisms against viral infections [36] . IFNs are commonly classified into two groups. Type I IFNs can be induced by virus infection and are comprised of several IFN-␣ isoforms, IFN-␤ and IFN-, which are produced by a wide variety of cells. Type II IFN, IFN-␥, is induced primarily by mitogenic or antigenic stimuli and is produced by select cells of the immune system including NK cells, CD4
ϩ Th lymphocytes, and CD8 ϩ cytotoxic suppressor cells [27] . Accordingly, this study evaluated if HRV16 has the capacity to induce type I IFN (IFN-␣) production by monocytic cells as well as examined the involvement of IFNs in mediating STAT1 phosphorylation and IP-10 release by monocytic cells. There exist at least 14 identified human isoforms of IFN-␣. We examined IFN-␣ release using an ELISA assay, which detected some but not all isoforms, and observed that primary monocytes exposure to HRV16 for 24 h causes a significant increase in IFN-␣ release. We also showed that ex vivo stimulation with physiologically relevant concentrations of IFN-␣ induced STAT1 phosphorylation and IP-10 release by monocytic cells. In addition, as our results demonstrate that simultaneous stimulation of monocytic cells with HRV16 and IFN-␣ results in IP-10 release at similar levels to that released upon HRV16 challenge alone, we suggest that these stimuli use the same intracellular mechanism to regulate IP-10 expression or that HRV16 and IFN-␣ together induce maximal IP-10 induction, thereby nullifying an additive effect. However, the latter idea is less likely given the additive effect of IP-10 release by monocytic cells exhibited upon simultaneous exposure to HRV16 and IFN-␥.
To test the concept that HRV16-stimulated STAT1 phosphorylation and IP-10 release by monocytic cells are linked to the autocrine/paracrine action of type I IFNs, we assessed HRV16-induced STAT1 phosphorylation and IP-10 production levels by monocytic cells pretreated with a neutralizing type I IFN receptor antibody. Two recent reports used the same technique to test if HRV16-induced IP-10 expression by epithelial cells was secondary to type I IFN receptor ligation and found conflicting conclusions [7, 18] . Investigations by Chen et al. [18] demonstrated that HRV16-stimulated STAT1 phosphorylation and IP-10 mRNA induction in differentiated tracheobronchial epithelial cells isolated from two donors were partially suppressed by the type I IFN receptor neutralizing antibody. Conversely, Spurrell et al. [7] observed that neutralizing the type I IFN receptor did not suppress HRV16-induced IP-10 mRNA induction in adenoidal epithelial cells isolated from three human donors but did attenuate IFN-␤-stimulated IP-10 mRNA induction. The conflicting results could be a result of differential regulation in epithelial cells derived from different tissues or that Chen et al. [18] used a high concentration of neutralizing IFN receptor antibody (20 g/mL) compared with 5 g/mL in the study by Spurrell et al. [7] . Our findings demonstrate that blocking ligand interaction with the type I IFN receptor, using 5 g/mL neutralizing antibody, attenuated HRV16-and IFN-␣-stimulated STAT1 phosphorylation and IP-10 release by monocytic cells but did not suppress IFN-␥-induced STAT1 phosphorylation or IP-10 production. These data are the first to demonstrate clearly that HRV16-stimulated STAT1 phosphorylation and IP-10 expression at the protein level in primary monocytic cells are linked to type I IFN receptor ligation.
In summary, although symptomatic HRV infections are associated with elevated levels of chemokines in the airway and nasal secretions, the intracellular regulation and production of cytokines and chemokines by airway immune cells in response to HRV challenge are largely unknown. Our findings indicate that primary monocytic cells become activated and release robust levels of IP-10 protein following HRV16 inoculation, which is independent of viral replication. Phosphorylation of STAT1 in monocytes also occurs following HRV16 challenge, and inhibition of the JAK/STAT pathway activity suppresses HRV16-stimulated IP-10 production. Type I IFN-␣ is also produced following monocytic cell exposure to HRV16; moreover, HRV16-induced STAT1 phosphorylation and production of IP-10 are attenuated by neutralization of the type I IFN receptor. Thus, the present work supports a model wherein HRV16-induced IP-10 release by human monocytic cells is modulated via autocrine/paracrine action of type I IFNs and subsequent type I IFN receptor/JAK/STAT pathway activity. Our findings demonstrating robust activation of human monocytic cells in response to replicative and/or nonreplicative HRV16 challenge further support the idea that there is a mechanistic disparity in the activation of airway macrophages compared with epithelial cells and further suggest that macrophages are likely active participants in promoting cytokine elaboration following HRV challenge in vivo.
